High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study
Open Access
- 23 November 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pediatrics
- Vol. 12 (1), 183
- https://doi.org/10.1186/1471-2431-12-183
Abstract
Despite changes in WHO guidelines, stavudine is still used extensively for treatment of pediatric HIV in the developing world. Lipoatrophy in sub-Saharan African children can be stigmatizing and have far-reaching consequences. The severity and extent of lipoatrophy in pre-pubertal children living in sub-Saharan Africa is unknown. In this cross-sectional study, children who were 3-12 years old, on antiretroviral therapy and pre-pubertal were recruited from a Family HIV Clinic in South Africa. Lipoatrophy was identified and graded by consensus between two HIV pediatricians using a standardized grading scale. A professional dietician performed formal dietary assessment and anthropometric measurements of trunk and limb fat. Previous antiretroviral exposures were recorded. In a Dual-Energy X-ray Absorbtiometry (DXA) substudy body composition was determined in 42 participants. Among 100 recruits, the prevalence of visually obvious lipoatrophy was 36% (95% CI: 27%–45%). Anthropometry and DXA measurements corroborated the clinical diagnosis of lipoatrophy: Both confirmed significant, substantial extremity fat loss in children with visually obvious lipoatrophy, when adjusted for age and sex. Adjusted odds ratio for developing lipoatrophy was 1.9 (95% CI: 1.3 - 2.9) for each additional year of accumulated exposure to standard dose stavudine. Cumulative time on standard dose stavudine was significantly associated with reductions in biceps and triceps skin-fold thickness (p=0.008). The prevalence of visually obvious lipoatrophy in pre-pubertal South African children on antiretroviral therapy is high. The amount of stavudine that children are exposed to needs review. Resources are needed to enable low-and-middle-income countries to provide suitable pediatric-formulated alternatives to stavudine-based pediatric regimens. The standard stavudine dose for children may need to be reduced. Diagnosis of lipoatrophy at an early stage is important to allow timeous antiretroviral switching to arrest progression and avoid stigmatization. Diagnosis using visual grading requires training and experience, and DXA and comprehensive anthropometry are not commonly available. A simple objective screening tool is needed to identify early lipoatrophy in resource-limited settings where specialized skills and equipment are not available.Keywords
This publication has 24 references indexed in Scilit:
- Body Fat Abnormality in HIV-Infected Children and Adolescents Living in EuropeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Effect of HIV Infection Status and Anti‐Retroviral Treatment on Quantitative and Qualitative Antibody Responses to Pneumococcal Conjugate Vaccine in InfantsThe Journal of Infectious Diseases, 2010
- Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous Adipocytes Treated with Nucleoside Analogue Reverse Transcriptase InhibitorsAntimicrobial Agents and Chemotherapy, 2010
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- Morphologic and metabolic abnormalities in vertically HIV-infected children and youthAIDS, 2009
- Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV‐Infected Subjects: A Randomized, Controlled StudyClinical Infectious Diseases, 2008
- Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatmentExpert Opinion on Pharmacotherapy, 2007
- Prevalence of lipodystrophy in HIV-infected children: a cross-sectional studyEuropean Journal of Pediatrics, 2006
- Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral ActivityHIV Research & Clinical Practice, 2005
- Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2001